ACADIA Pharmaceuticals (ACAD) announces Pimavanserin has met its primary and key secondary...

|About: ACADIA Pharmaceuticals Inc. (ACAD)|By:, SA News Editor

ACADIA Pharmaceuticals (ACAD) announces Pimavanserin has met its primary and key secondary endpoints in its Phase III Parkinson's Psychosis Trial. Shares are halted in premarket trading. (PR)